Gadolinium based Contrast Agents (GBCAs): FDA announces new class warnings:
Date : 19-02-2018
Link : https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm589580.htm
Gadolinium retention has until now, not been directly associated with any adverse effects in patients with normal kidney function. However, after additional review and consultation with the Medical Imaging Drugs Advisory Committee, FDA is requiring several actions to alert healthcare professionals and patients about gadolinium retention after an MRI using GBCA, and actions that can help minimize problems.